Maplight Therapeutics

This study is checking the safety of a drug called ML-004 in about 120 people aged 12 to 46 with autism. All participants have already completed an earlier study of the same drug. The main goal is to see what side effects occur, and the study is open-label, meaning everyone knows…

This study tests an investigational drug called ML-004 to see if it can help improve social communication in adolescents and adults with autism spectrum disorder. About 150 participants aged 12 to 45 will receive either ML-004 or a placebo for a set period. The main goal is to me…